SWOG clinical trial number
SWOG-9450

Prostate Cancer Intervention Versus Observation Trial

Closed
Phase
Published
Abbreviated Title
Local Prostate
Activated
05/01/1995
Closed
11/30/2001

Research committees

Genitourinary Cancer

Eligibility Criteria Expand/Collapse

Age < /= 75 yrs; Clinically localized tissue documented adenoca. of the prostate, (T1 a,b,c, - T2 a,b,c, NX, M0); Diagnosis of CAP within previous 6 mo; PSA < 50 ng/ml,(if currently taking finasteride, PSA < 25 ng/ml); no prior pelvic RT, chemo, anti-androgen or androgen deprivation therapy except 5-alpha-reductase inhibitors; no prior surg. other than TURP/TUIP/dilation/simple prostatectomy; no current estrogen or androgen blocking therapy; no evidence of metastatic dz., no significant medical conditions or high surgical risks (MI within last 6 mo, unstable angina, severe CHF pulmonary or hepatic dz, see p. 31 of the Manual of Operations for complete description).

Publication Information Expand/Collapse

2012

Prostate Cancer - uncertainty and a way forward

IM Thompson;C Tangen New England Journal of Medicine 367(3):270-271 (commentary)

PMid: PMID22808963 | PMC number: n/a (commentary)

1997

The prostate cancer intervention versus observation trial (PIVOT).

TJ Wilt;MK Brawer Oncology 11(8):1133-1139

Other Clinical Trials

SWOG Clinical Trial Number
S2210

S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"

Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
S2200
SWOG Clinical Trial Number
CTSU/A031901